Details of the Drug

General Information of Drug (ID: DM5LJCI)

• Drug Name: Eptinezumab

Indication

Disease Entry	ICD 11	Status	REF
Migraine	8A80	Approved	[1]

• Sequence:
  >heavy chain
  EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYYMNWVRQAPGKGLEWVGVIGINGATYYA
  SWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVTVSSASTKGPSVF
  PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV
  TVPSSSLGTQTYICNVNHKPSNTKVDARVEPKSCDKTHTCPPCPAPELLGGPSVTLFPPK
  PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVL
  TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT
  CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
  VMHEALHNHYTQKSLSLSPGK
  >Light chain
  QVLTQSPSSLSASVGDRVTINCQASQSVYHNTYLAWYQQKPGKVPKQLIYDASTLASGVP
  SRFSGSGSGTDFTLTISSLQPEDVATYYCLGSYDCTNGDCFVFGGGTKVEIKRTVAAPSV
  FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL
  SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
• ADMET Property:
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 336.4 mg/L [2]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 4.8 h [2]
  Bioavailability: The bioavailability of drug is 100% [2]
  Clearance: The clearance of drug is 0.006 L/h [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 27 days [3]
  Vd: The volume of distribution (Vd) of drug is 3.7 L [3]
• Cross-matching ID:
  DrugBank ID: DB14040
  TTD ID: D0H6QD

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcitonin gene-related peptide (CALC)	TTAFORY	NOUNIPROTAC	Inhibitor	[1]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] EconoTimes Business Article: Alder BioPharmaceuticals? New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals (Up to 32.5 days) and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine
• [3] FDA Approved Drug Products: Vyepti (eptinezumab-jjmr) for intravenous injection